Friday, August 23, 2019
Home Partner Profiles Neurosteer and the research being done to tackle neurological disorders

Neurosteer and the research being done to tackle neurological disorders

Neurosteer Inc.

Neurosteer™ has developed a solution for the early detection and more effective treatment of a variety of neurological disorders.

It consists of a medical-grade wearable device and cloud-based system that provides real-time monitoring and assessment of brain activity. The company’s current focus is on delivering objective biomarkers that identify the early onset of Parkinson’s, Alzheimer’s, dementia and epilepsy.

 Brain health

Modern medicine offers a number of standard tests with objective metrics and assessment criteria – as well as real-time and continuous monitoring – for a wide range of medical conditions. These include blood pressure tests for hypertension, biopsies for cancer, glucose tests for diabetes, and a collection of other standard blood tests.

By contrast, there are no objective metrics nor standard tests for assessing and monitoring most neurological and psychiatric disorders, while existing tests for the brain are expensive and hard-to-administer.

 

From initial screening to continuous monitoring

Compared to a functional MRI – the current “gold standard” for brain activity screening and assessment – Neurosteer is inexpensive, portable and unobtrusive, can be used in a clinical setting for initial assessment and then as part of a patient’s normal daily routine for up to continuous 24/7 monitoring.

It allows the patient to perform cognitive or physical tasks while being monitored, provides immediate feedback on the response to and the efficacy of drugs and/or neurostimulation, and delivers interpreted results in real-time while the monitoring is still underway.

 

Breakthrough product

Neurosteer uses an adhesive forehead strip connected to a pocket-sized device that wirelessly transmits sensor data to the cloud for proprietary signal processing. Advanced algorithms then decompose the single EEG channel into 100+ individual components for real-time analysis and display on a web-based dashboard.

The result is more affordable screening, continuous patient monitoring, and optimised neurostimulation and drug selection, all leading to improved neurological treatment and outcome of clinical trials.

 21st century technology

Neurosteer advances the century-old EEG into the 21st century, replacing dozens of electrodes with a single three-electrode strip, ultra-sensitive electronics, advanced signal processing software, sophisticated machine learning algorithms, and big data analytics. The sensor data is captured, decomposed and interpreted into a multi-channel representation of brain activity and objective biomarkers, all in real-time and on a continuous basis.

New standard of care

Neurosteer delivers a new brain activity representation that can be used to screen, assess and monitor a large number of neurological conditions. Just as blood pressure maintenance went from the specialised purview of the cardiologist to the general practitioner with the now ubiquitous blood pressure monitor, Neurosteer is offering an off-the-shelf product that can become a standard general-purpose neurological diagnostic tool for use not only by neurologists but also by anyone in the medical community.

 About the Company

Neurosteer’s initial technology was developed at Tel Aviv University, Israel, by Nathan Intrator, PhD, a professor of Computer Science and Neuroscience. Dr. Intrator has been a well-known brain researcher and a leading expert on signal processing for over twenty-five years and founded Neurosteer Inc. in 2015 to further develop and commercialise the Neurosteer technology. With offices in New York, California and Israel, the company’s patented product is currently being validated in clinical trials and used by pharmaceutical companies for patient screening and efficacy testing of new drugs.

 

 

AREAS OF EXPERTISE

Early detection and more effective treatment of a variety of neurological disorders. The company’s current focus is on delivering objective biomarkers that identify the early onset of Parkinson’s, Alzheimer’s, dementia and epilepsy.

RESEARCH INTERESTS
  • Neuroscience
  • Brain research
  • Psychiatric disorders
RECENT PUBLICATIONS

Profile in Health Europa Quarterly – Issue 7

Pin It on Pinterest